Leucovorin
Active ingredient: Leucovorin Calcium
In short: Leucovorin is indicated to reduce the toxicity of: Methotrexate in adult patients with impaired methotrexate elimination, and Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult patients. Leucovorin is indicated for the treatment of cerebral folate tran
What is Leucovorin used for?
Leucovorin is indicated to reduce the toxicity of:
Methotrexate in adult patients with impaired methotrexate elimination, and
Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult patients.
Leucovorin is indicated for the treatment of cerebral folate transport deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD).
Limitations of Use
Leucovorin is not recommended for use in patients with a deficiency of methenyltetrahydrofolate synthetase (MTHFS) because MTHFS is a primary enzyme in the metabolism of leucovorin to 5-methenyltetrahydrofolate (5-MTHF) .
Leucovorin is not indicated for the treatment of pernicious anemia or other megaloblastic anemias, due to the lack of vitamin B12, because of the risk of progression of neurologic manifestations despite hematologic remission.
Leucovorin dosage
Each indication has a different method for calculating the dosage (i.e., fixed dosage, body surface area-based dosage, or body weight-based dosage). Ensure that the correct method for calculating the dosage is used .
Leucovorin is for oral administration only and can be taken with or without food . Crushing of leucovorin tablets and mixing with food or liquid (e.g., water, breastmilk, infant formula) has been reported in literature. If administering via this method, administer immediately after mixing.
Administer leucovorin as soon as possible after a folic acid antagonist or DHFR inhibitor overdose and within 24 hours of methotrexate administration when there is impaired methotrexate elimination. The effectiveness of leucovorin decreases as the time interval between leucovorin administration and the folic acid antagonist or DHFR inhibitor increases.
For patients with impaired methotrexate elimination, monitor serum methotrexate concentrations and serum creatinine to determine the recommended dosage and duration of leucovorin.
For patients with impaired methotrexate elimination and in patients following a methotrexate overdose, administer intravenous fluids (3 Liters per day) and alkalinize the urine to maintain a urine pH of 7.0 or greater.
The recommended leucovorin dosage to reduce methotrexate toxicity in patients with impaired methotrexate elimination:
10 mg/m2 (up to 25 mg) orally every 6 hours until the serum methotrexate levels are less than 10-8M (0.01 micromolar).
When a dosage greater than 25 mg every 6 hours is needed for this use, leucovorin is not recommended because this dosage and the formulation may be inadequate to treat significant methotrexate toxicity, resulting in possible methotrexate toxicity fatalities. Refer to the prescribing information for leucovorin injection for dosage recommendations.
If the 24-hour serum creatinine has increased 50% over baseline or if the 24-hour methotrexate level is greater than 5 x 10-6 M or the 48-hour level is greater than 9 x 10-7 M, higher doses of leucovorin are needed; discontinue oral administration of leucovorin and administer leucovorin intravenously or intramuscularly. Refer to the prescribing information for leucovorin injection for the appropriate dosage and duration.
In patients who experience non-oliguric renal failure, continue leucovorin, hydration and alkalinization of the urine (pH of 7.0 or greater) until the methotrexate level is 0.05 micromolar.
Extend the duration of leucovorin administration for an additional 24 hours in subsequent courses of methotrexate in patients who experience significant methotrexate toxicities, impaired methotrexate elimination including third-space fluid accumulation and inadequate hydration, or renal impairment. …
How to take Leucovorin — instructions & advice from the label
Administration Instructions
Advise patients or caregivers that leucovorin tablets may be dissolved in an age-appropriate liquid (e.g., water, breastmilk, or infant formula) or crushed and mixed with soft food before administration. If leucovorin is to be administered in this manner, instruct patients or caregivers to administer the dissolved or mixed product immediately after mixing .
Hypersensitivity Reactions
Advise patients to inform their healthcare provider if they develop a hypersensitivity reaction while taking leucovorin .
Drug Interactions
Advise patients to inform their healthcare providers of all concomitant drugs, including prescription drugs, nonprescription drugs, vitamins, and herbal products .
Rx only
Manufactured and Distributed by:
Leading Pharma, LLC
Fairfield, NJ 07004, USA
Rev.03 03/26
Warnings & precautions
Do not take this medicine if: Leucovorin is contraindicated in patients with a history of hypersensitivity reaction depending on indication as described below, to leucovorin (folinic acid), levoleucovorin, folic acid, or any component of leucovorin :
Folic acid antagonist or DHFR inhibitor toxicity: history of severe hypersensitivity reaction
FOLR1-CFTD: history of any hypersensitivity reaction
Reactions have included anaphylactic reactions .
Hypersensitivity reactions, including anaphylactic reactions and urticaria, have been reported following the administration of leucovorin. Leucovorin is contraindicated for the treatment of folic acid antagonist or DHFR inhibitor toxicity in patients with a history of a severe hypersensitivity reaction and for the treatment of FOLR1-CFTD in patients with a history of any hypersensitivity reaction to leucovorin, levoleucovorin, folic acid, or any component of leucovorin . Withhold or permanently discontinue leucovorin based on the severity of hypersensitivity.
Leucovorin side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity Reactions .
The following adverse reactions have been identified during postapproval use of leucovorin (d,l-leucovorin) or levoleucovorin (l-leucovorin). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Dermatologic: Pruritus, rash.
Respiratory: Dyspnea.
Other Clinical Events: Rigors, temperature change.
Safety information for the treatment of FOLR1-CFTD with oral leucovorin is limited. The available evidence is based on published case reports .
Drug interactions
Certain Antiepileptic Drugs
Increase monitoring for seizure activity in leucovorin-treated patients taking certain concomitant antiepileptic drugs.
Folic acid in high doses may reduce the effectiveness of certain antiepileptic drugs (e.g., phenobarbital, phenytoin, and primidone) and thereby increase the frequency of seizures in susceptible patients, including pediatric patients. It is not known whether folinic acid, including leucovorin, has the same effects; however, both folic and folinic acids, including leucovorin, share some common metabolic pathways.
Trimethoprim-Sulfamethoxazole
Avoid concomitant use of leucovorin with trimethoprim-sulfamethoxazole.
The effectiveness of trimethoprim-sulfamethoxazole can be decreased if used concomitantly with leucovorin, which was associated with increased rates of treatment failure and mortality in patients with HIV infection who receive trimethoprim-sulfamethoxazole for the acute treatment of
Pneumocystis jirovecii
pneumonia.
Fluorouracil
Leucovorin may enhance the toxicity of fluorouracil. Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil. Concomitant granulocytopenia and fever were present in some but not all of the patients. …
About this medicine
Leucovorin Calcium Tablets contain either 5 mg, 10 mg, 15 mg or 25 mg leucovorin as the calcium salt of N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L- glutamic acid and the inactive ingredients Colloidal Silicon Dioxide, Croscarmellose Sodium, Magnesium Stearate, Microcrystalline Cellulose and Pregelatinized Starch. This is equivalent to 5.4 mg, 10.8 mg, 16.21 mg or 27.01 mg of anhydrous leucovorin calcium.
Leucovorin is a water soluble form of reduced folate in the folate group; it is useful as an antidote to drugs which act as folic acid antagonists. These tablets are intended for oral administration only. The structural formula of leucovorin calcium is:
How it works: Levoleucovorin, a reduced folate and the pharmacologically active isomer of leucovorin (5-formyl-tetrahydrofolic acid), can mitigate the toxic effects of folate antagonists, including methotrexate and other agents that inhibit dihydrofolate reductase (DHFR). Inhibition of DHFR blocks the formation of tetrahydrofolate, an essential cofactor for DNA synthesis and repair. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c8102043-79f2-421a-b849-94bac19007a6. Read the full official label on DailyMed.